Our experience on pain palliation of bone metastasis with Sr-89 or Sm-153 in cancer patients resistant to a conventional analgesic therapy. A retrospective study

Clinica Terapeutica

Volumn 160, Issue 3, 2009, Pages 193-199

  Montesano, Teresa ^a   Giacomobono, S ^a   Acqualagna, G ^a   Colandrea, M ^a   Di Nicola, A ^a   Travascio, L ^a   Ciancamerla, M ^a   D'Apollo, R ^a   Toteda, M ^a   Ugolini, F ^a   Filesi, M ^a   Ronga, G ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Bone metastases; Bone pain; Bone seeking radionuclides; Radiometabolic therapy

Indexed keywords

ALKALINE PHOSPHATASE; ANALGESIC AGENT; ANTINEOPLASTIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; ETHYLENEDIAMINETETRAMETHYLENE PHOSPHONIC ACID SM 153; OXIDRONATE TECHNETIUM TC 99M; PROSTATE SPECIFIC ANTIGEN; RADIOPHARMACEUTICAL AGENT; STRONTHIUM C 89; TELOPEPTIDE; UNCLASSIFIED DRUG;

ADULT; AGED; ANALGESIA; ARTICLE; BONE METASTASIS; BONE SCINTISCANNING; BREAST CANCER; CANCER PAIN; CANCER PALLIATIVE THERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG UPTAKE; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; KARNOFSKY PERFORMANCE STATUS; LEUKOCYTE COUNT; LEUKOPENIA; LUNG CANCER; MALE; PAIN ASSESSMENT; PROSTATE CANCER; PROTEIN BLOOD LEVEL; QUALITY OF LIFE; QUESTIONNAIRE; RADIOISOTOPE THERAPY; SCORING SYSTEM; SINGLE DRUG DOSE; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ANALGESICS; ANALGESICS, NON-NARCOTIC; BONE NEOPLASMS; COMBINED MODALITY THERAPY; DRUG RESISTANCE; FEMALE; HUMANS; MALE; MIDDLE AGED; ORGANOMETALLIC COMPOUNDS; ORGANOPHOSPHORUS COMPOUNDS; PAIN; PALLIATIVE CARE; RETROSPECTIVE STUDIES; STRONTIUM; STRONTIUM RADIOISOTOPES;

EID: 67749143996     PISSN: 00099074     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Coleman RE. Metastatic bone diseas: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev 2001; 27:165-176 (Pubitemid 32452017)
2. Foley KM. The treatment of cancer pain. N Engl J Med 1985; 313:84-95
3. Nielsen OS, Munro AJ, Tannock IF. Bone metastases: Pathophysiology and management policy. J Clin Oncol 1991;9:509-524
4. World Health Organization. Cancer Pain Relief and Palliative Care: Report of a WHO Expert Committee. Geneva, Switzerland: World Health Organization 1990
5. Saad F, Lipton A. Clinical benefits and considerations of bisphosphonate treatment in metastatic bone disease. Semin Oncol. 2007 Dec; 34(6 Suppl 4):S17-23
6. Migliorati CA, Siegel MA, Elting LS. Bisphosphonate-associated osteonecrosis: a long-term complication of bisphosphonate treatment. Lancet Oncol 2006; 7(6):508-514
7. Pandit-Taskar N, Batriaki M, Divgi CR. Radiopharmaceutical therapy for palliation of bone pain fro osseus metastases. J Nucl Med 2004; 45(8):1358-1365 (Pubitemid 47618536)
8. Singh A, Holmes RA, Farhanghi M, et al. Human pharmacokinetics of samarium-153 EDTMP in metastatic cancer. J Nucl Med 1989; 30:1814-1818 (Pubitemid 19279785)
9. Lewington VJ. Bone-Seeking Radionuclides for therapy. J Nucl Med 2005; 456(1):38S
10. Paszkowski AL, Hewitt DJ, Taylor A Jr. Disseminated intravascular coagulation in a patient treated with strontium-89 for metastatic carcinoma of the prostate. Clin Nucl Med 1999; 24:852-854
11. Caraceni A, Cherny N, Fainsinger R et al. Pain measurements tools and methods in clinical research in palliative care: recommendations of an Expert Working Group of the European Association of Palliative Care. J Pain Symptom Manage 2002; 23:239-255 (Pubitemid 34219075)
12. Littman GS, Walker BR, Schneider BE. Reassessment of verbal and visual analog ratings in analgesic studies. Clin Pharmacol Ther 1985; 38:16-23
13. Mor V, Laliberte L, Morris JN, et al. The Karnofsky Performance Status Scale. An examination of its reliability and validity in a research setting. Cancer 1984; 53:2002-2007
14. Schaafsma J, Osoba D. The Karnofsky Performance Status Scale re-examinated: a cross-validation with the EORT-C30. Qual Life Res 1994; 3:413-424
15. Farhanghi M, Holmes RA, Volkert WA, et al. Samarium 153-EDTMP: pharmacokinetic, toxicity and pain response using an escalating dose schedule in tratment of metastatic bone cancer. J Nucl Med 1992 33 (8):1451-1458
16. McEwan AJ, Amyotte GA, McGowan DG et al. A retrospective analysis of the cost effectiveness of treatment with Metastron (89 Sr-chloride) in patients with prostate cancer metastatic to bone. Nucl Med Communications 1994; 15:499-504
17. Kasalicky J, Krajska V. The effect of repeated Strontium-89 chloride therapy on bone pain in patients with skeletal cancer metastases. Eur J Nucl Med 1998; 25:1362-1367 (Pubitemid 28464109)
18. Pons F, Herranz R, Garcia A, et al. Strontium-89 for palliation of pain from bone metastases in patients with prostate and breast cancer. Eur J Nucl Med 1997; 24:1210-1214 (Pubitemid 27477612)
19. Enrique O, Zhonyun P, Prma EP, et al. Efficacy and toxicity of Sm-153 EDTMP in the palliative treatment of painful bone metastases. World J Nucl Med 2002; 1:21-27
20. Tian JH, Zhang JM, Hou QT, et al. Multicentre trial on the efficacy and toxicity of single-dose samarium-153-ethylene diamine tetramethylene phosphonate as a palliative treatment for painful skeletal metastases in China. Eur J Nucl Med 1999; 26: 2-7
21. Maini CL, Bergomi S, Romano L, et al. 153Sm-EDTMP for bone pain palliation in skeletal metastases. Eur J Nucl Med 2004; 31:71-78 (Pubitemid 38833047)
22. Serafini AN. Samarium Sm-153 lexidronam for the palliation of bone pain associated with metastases: Cancer Suppl 2000; 88:2934-2939
23. Saramatunga RC, Thomas SR, Hinnefeld JD, et al. A Monte Carlo simulation model for radiation dose to metastatic skeletal tumor from Rhenium-186 (Sn)-HEDP. J Nucl Med 1995; 36:336-350
24. Sciuto R, Festa A, Rea S, et al. Effects of low-dose cisplatin on 89 Sr therapy for painful bone metastases from prostate cancer: a randomized clinical trial. J Nucl Med 2002; 43 (1):79-86 (Pubitemid 34101193)
25. Ricci S, Boni G, Pastina I, et al. Clinical benefict of bone-targeted radiometabolic therapy with 153 Sm-EDTMP combined with chemotherapy in patients with metastatic hormone-refractory prostate cancer. Eur J Nucl Med Mol Imaging 2007; 34:1023-1030 (Pubitemid 46919554)
26. Dafermou A, Colamussi P, Giganti M, et al. A multicentre observational study of radionuclide therapy in patients with painful bone metastases of prostate cancer. Eur J NucL Med. 2001; 28:788-798 (Pubitemid 32662540)
27. Menda Y, Bushnell DL, Williams RD, et al. Efficacy and safety of repeated Samarium-153 lexidronam treatment in a patient with prostate cancer and metastatic bone pain. Clin Nucl Med. 2000; 25:698-700 (Pubitemid 30664434)
28. De Klerk JM, Van het Schip AD, Zonnenberg BA, et al. Evaluation of thrombocytopenia in patients treated with rhenium-186-HEDP: guidelines for individual dosage recommendations. J Nucl Med 1994; 35:1423-1428
29. Fischer M. New aspects of radionuclide therapy in metastatic bone pain. Anticancer Res 2000; 20(6D):5183-5189 (Pubitemid 32319104)